RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Aptar Pharma, leader in respiratory drug delivery solutions, and RDD Online® are pleased to announce their co-organization of RDD® Europe 2025, which will be held in-person from Tuesday, May 6 to Friday, May 9, 2025 at the Estoril Congress Center in Estoril, Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227163353/en/
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online (Graphic: Business Wire)
Celebrating 20 years of RDD Europe and one of the largest and highly regarded international respiratory health conferences, RDD Europe 2025 will host over 500 scientists, engineers, clinicians and business professionals engaged in all aspects of nasal and pulmonary drug delivery.
With curated and peer reviewed content organized in six Knowledge Spaces, speakers, workshops, poster presenters and exhibitors will share timely, actionable insights under the following themes:
- Bench to Bedside: Emerging Therapies and Clinical Advances
- Inspiring Dry Powder Inhalation: Formulation Science and Device Design
- MDIs in Transition: Evolving Science and Regulations
- Advanced Inhalation: AI and Data Driven Design
- Aqueous Agenda: Soft Mist Inhalers and Nebulizer Advances
- Nasal Spotlight: Advances in Systemic and Nose-to-Brain Delivery.
Twelve delegate-selectable industry Workshops will take place on Wednesday, May 7, providing practical and interactive demonstrations of innovative technologies, products and capabilities in a small group setting.
An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity for networking, with 70 exhibit tables and 72 posters showcasing academic and industry research, and development breakthroughs across established and emerging nasal and pulmonary drug delivery platforms.
To complement in-person activities, RDD Europe 2025 will also include extended online access from April 29 to June 30, 2025 to on-demand presentations and company profiles. In addition, almost 3,000 peer-reviewed speaker and poster papers will be available to delegates for 12 months after the conference.
The conference will open with a Welcome Cocktail Reception on the evening of Tuesday, May 6, and Aptar Pharma will sponsor a Gala Dinner at a scenic location in Estoril on Thursday, May 8.
As a global leader in OINDP device design and technology, Aptar Pharma is proud to be a Co-Organizer of RDD Europe 2025 and will host a workshop on May 7. Entitled “Ready for Clinical Trials in 1 Hour: A Roadmap to Success,” this workshop will be co-presented by Jonathan Mulpas, Director Business Development Pulmonary Category, Aptar Pharma, Will Ganley, Manager, Computational Pharmaceutics, Nanopharm, an Aptar Pharma company, and Carolina Dantas, Head of Medical & Scientific Affairs, Pulmotree.
“Estoril is a great location to celebrate 20 years of RDD Europe conferences. I can’t wait to catch up with friends and organizations who have returned year after year since RDD Europe 2005 was first held in Paris,” commented Richard Dalby, one of the conference organizers. “So much has changed since then, and the innovation I’ve witnessed seems poised to have direct benefits on patient health, healthcare provider choice and environmental sustainability.”
Added Carolyn Penot, Director of Operational Marketing at Aptar Pharma, “RDD Europe 2025 is a must-attend event, and this year’s Knowledge Spaces will represent the latest thinking in nasal and pulmonary drug delivery. We look forward to celebrating 20 years of RDD Europe with our conference participants.”
To register as a delegate or learn more about sponsorship opportunities, visit the RDD Europe 2025 website.
About RDD Online
RDD Online manages the organization of Respiratory Drug Delivery conferences in the U.S., and partners with Aptar Pharma to run RDDevents in Europe and Asia. These international conferences, focused on technologies and solutions to improve patient health, routinely attract over 500 delegates from 25 countries representing academia, industry and regulatory agencies. RDD Online also supplies realistic mouth throat models, Nephele mixing inlets and dose collection tubes. We offer scientific and technical publications, web-based training, and a company directory of organizations active in pulmonary and nasal drug delivery. For more information, please visit www.rddonline.com.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227163353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 09:15:00 CEST | Press release
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell productionIn high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic responsewith the majority (82%) realizing a complete responseA reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic responseInitial results demonstrate a favorable safety profile – no dose limiting toxicities were reported, a maximum tolerated dose was not reached and 98% of patients remained on treatmentIncyte will host an in-person analyst and investor event highlighting this data at EHA today, Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 -1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced the first
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 15:14:00 CEST | Press release
The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compare
Capcom’s Devil May Cry 5 Sales Top 10 Million Units!13.6.2025 15:00:00 CEST | Press release
– Capcom further enhances global brand awareness with its Single Content Multiple Usage strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide cumulative sales of Devil May Cry 5 havesurpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613788747/en/ Devil May Cry 5 logo In Devil May Cry 5, players can enjoy thrilling, high-speed gameplay, stylish action, and beautiful graphics, depicted with intricate realism thanks to Capcom’s proprietary RE ENGINE. The title has garnered strong support from users due to its exceptional gameplay experience, leading to expanded sales as a catalog title since its release. Capcom provided an even more advanced story and action elements in the game with the addition of a new playable character, and more recently, on April 3, 2025, the company released the new Devil May Cry animated series on Netflix, in line with the company’s Single Content Multiple Us
realme Summer Party: a Major Event and an Exclusive Collaboration with TikTok13.6.2025 14:59:00 CEST | Press release
realme, one of the world's leading smartphone brands, held a summer festival on June 6 and 7 at the foot of the Eiffel Tower with fun activities. Visitors could try their hand at ring throwing, immortalize their moments at the Photobooth van, or leave with exclusive gifts. Each participant received a voucher to exchange for a prize in the dedicated area for a successful festive experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612984325/en/ Live photo from realme Summer Party and the newly launched GT 7 Dream Edition A festive event at the foot of the Eiffel Tower The event was a great success, thanks to the engagement of participants on-site and through social media. Many visitors shared photos and videos, creating a dynamic and friendly atmosphere, amplified by the realme community. An exclusive collaboration between realme and TikTok This collaboration between realme and TikTok extends beyond this event. Indee
Take It Slow: Why Ireland Is the Perfect Destination for the ‘Unrushed’ Traveller13.6.2025 14:30:00 CEST | Press release
Tourism Ireland--In a world that’s always rushing, Ireland is extending a gentle invitation: take your time. With its winding coastal trails, soul-soothing landscapes, and deep-rooted traditions, Ireland is emerging as one of Europe’s most natural fits for slow tourism — a growing global travel trend focused on deeper, more meaningful experiences over fast-paced itineraries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612345730/en/ Cycling on greenway, County Waterford From misty mornings in the Burren to long afternoons along the Wild Atlantic Way, Ireland rewards those who slow down. Whether it’s connecting with local craftspeople, foraging along the coast, lingering over storytelling sessions in a pub, or staying in family-run farmhouses — the country’s charm reveals itself not in a rush, but in the details. What is ‘Slow Tourism’? Slow tourism encourages travellers to engage more fully with a destination, spending
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom